- 1. c mas
- [ ] (UMLS (CSP) C0599900) =Gene or Genome ;
| - 23. CMFP
- (UMLS (NCI) C0055985) =Therapeutic or Preventive Procedure
|
- 2. c myb
- [ ] (UMLS (CSP) C0751993) =Gene or Genome ;
| - 24. CMFP-VA
- (UMLS (NCI) C0279327) =Therapeutic or Preventive Procedure
|
- 3. C-MALT
- (UMLS (NCI) C1367653) Cutaneous Immunocytoma;
Marginal Zone B Cell Lymphoma of Skin;
Marginal Zone B Cell Lymphoma of the Skin;
Primary Cutaneous Marginal Zone B Cell Lymphoma of Mucosa-Associated Lymphoid Tissue;
Primary Cutaneous Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue;
SALT Lymphoma;
Skin-Associated Lymphoid Tissue Lymphoma =Neoplastic Process ;
| - 25. CMFPT
- (UMLS (NCI) C0055986) =Therapeutic or Preventive Procedure
|
- 4. c-mer Proto-oncogene Tyrosine Kinase
- [Expressed in monocytes, bone marrow, and tissues of epithelial and reproductive origin by human MERTK Gene (AXL/UFO Family), 999-aa 110-kDa (precursor) Receptor Tyrosine Kinase MERTK contains 2 extracellular N-terminal Ig-like C2-type domains and 2 membrane proximal fibronectin type III domains, a putative transmembrane segment, a tyrosine kinase KWIAIES domain, several N-glycosylation sites, and tyrosine phosphorylation sites. Not expressed in normal B- and T-lymphocytes, MERTK is expressed in numerous neoplastic B-and T-cell lines. MERTK defects cause retinitis pigmentosa. (NCI) ( NCI )] (UMLS (NCI) C1259418) EC 2.7.1.112;
MERTK;
Receptor Tyrosine Kinase MerTK =Amino Acid, Peptide, or Protein; Enzyme; Receptor | - 26. CMFT
- (UMLS (NCI) C0279502) =Therapeutic or Preventive Procedure
|
- 5. C-MER Proto-Oncogene Tyrosine Kinase Gene
- [This gene plays a role in tissue homeostasis and mutations in the gene are associated with the onset of autosomal recessive retinitis pigmentosa. ( NCI )] (UMLS (NCI) C1364081) MERTK;
MERTK Gene =Gene or Genome | - 27. CMFVP(T)
- (UMLS (NCI) C0279333) =Therapeutic or Preventive Procedure
|
- 6. C-MET
- [The MET proto-oncogene encodes hepatocyte growth factor receptor, a cell surface receptor-like tyrosine kinase comprised of disulfide-linked 50 kD (alpha) and 145 kD (beta) subunits. In the fully processed c-MET product, the alpha subunit is extracellular, and the beta subunit has extracellular, transmembrane, and tyrosine kinase domains, as well as sites of tyrosine phosphorylation. The beta subunit of the c-MET proto-oncogene product is the cell surface receptor for hepatocyte growth factor. c-MET is related to the insulin receptor and ABL oncogene. (from OMIM 164860 and NCI) ( NCI )] (UMLS (NCI) C1456828) Hepatocyte Growth Factor Receptor;
HGFR;
HGF-SF Receptor;
MET Gene Product =Amino Acid, Peptide, or Protein; Receptor | - 28. CMN
- [A low grade childhood congenital malignant neoplasm arising from the kidney. It is characterized by the presence of fibroblastic cells. The majority of cases occur in the first year of life. Complete excision is usually associated with an excellent prognosis. ( NCI )] (UMLS (NCI) C1332965) Congenital Mesoblastic Nephroma;
Mesoblastic Nephroma;
=Neoplastic Process |
- 7. c-Met-related Tyrosine Kinase
- [A member of the MET receptor family. The protein is membrane-spanning disulfide-linked heterodimer with intracellular tyrosine kinase activity. It is synthesized as a single polypeptide which is processed to the 185-kD heterodimer of 35-kD (alpha) and 150-kD (beta) subunits joined by the predicted disulfide linkage. The protein is a specific cell surface receptor for macrophage stimulating protein. Targeted expression in mice results in frequent, multiple lung tumors. It may also play a role in progression of some colorectal cancers (from OMIM, Oncogene 2002;21:6382-6 and Oncogene 2003;22:186-97) ( NCI )] (UMLS (NCI) C0215510) =Amino Acid, Peptide, or Protein; Enzyme; Receptor
| - 29. CMOPP
- (UMLS (NCI) C0107744) =Therapeutic or Preventive Procedure ;
|
- 8. C-MOPP
- [A derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin's lymphoma. Also used for the treatment of non-Hodgkin's lymphoma. ( NCI )] (UMLS (NCI) C0110666) =Therapeutic or Preventive Procedure
| - 30. CMP (cytidine monophosphate)
- [Cytidine (dihydrogen phosphate). A cytosine nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position. ( MSH )] (UMLS (CSP) C0010729) =Nucleic Acid, Nucleoside, or Nucleotide
|
- 9. C-MOS
- [Cellular proteins encoded by the c-mos genes (GENES, MOS). They function in the cell cycle to maintain MATURATION PROMOTING FACTOR in the active state and have protein-serine/threonine kinase activity. Oncogenic transformation can take place when c-mos proteins are expressed at the wrong time. ( NCI )] (UMLS (NCI) C0072454) =Amino Acid, Peptide, or Protein; Enzyme ;
| - 31. CMP INT ORTH DEV/GFT NOS
- [ ] (UMLS (ICD9CM) C1561654) Unspecified mechanical complication of internal orthopedic device, implant, and graft;
=Pathologic Function |
- 10. C-MPL Ligand
- [A colony-stimulating factor that stimulates the production of blood cells, especially platelets, during chemotherapy. It is a cytokine that belongs to the family of drugs called hematopoietic (blood forming) agents. ( NCI )] (UMLS (NCI) C0040052) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 32. CMS (formerly HCFA )Procedure Codes (HCPCS)
- (UMLS (HL7) C1550211) =Intellectual Product =Code;
|
- 11. C-MPL Ligand
- (UMLS (NCI) C0392939) =Amino Acid, Peptide, or Protein; Pharmacologic Substance
| - 33. CMS (formerly HCFA) Common Procedure Coding System
- (UMLS (HL7) C1550205) =Intellectual Product =Code;
|
- 12. c-Myb
- [Encoded by human MYB Gene as 6 alternative isoforms, 640 aa 72-kDa nuclear c-MYB protein is a DNA-binding transcriptional activator critical for hematopoietic progenitor cell proliferation and differentiation. MYB contains 3 N-terminal MYB-like DNA-binding domains that specifically recognize YAAC[GT]G, a central transcriptional activation domain and a C-terminal transcriptional repression domain. MYB may interact with HIPK2 and NLK; phosphorylation by NLK on multiple sites may induce proteasomal degradation. Ubiquitination may be mediated by SIAH1. ( NCI )] (UMLS (NCI) C0072473) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 34. CMV
- [widely occurring intracellular herpesvirus characterized by narrow host specificity and slow reproduction (latency); causes a variety of pathologies in mammals, including AIDS related oculopathy in humans. ( CSP )] (UMLS (CSP) C0010825) =Virus ;
=Betaherpesvirinae;
|
- 13. c-Myb LR-3001
- (UMLS (NCI) C0253788) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 35. CMV
- (UMLS (NCI) C0278819) =Therapeutic or Preventive Procedure
|
- 14. c-MYC Protein
- [Product of the c-myc proto-oncogene. A nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. ( NCI )] (UMLS (NCI) C0080065) =Amino Acid, Peptide, or Protein; Biologically Active Substance
| - 36. CMV Colitis
- (UMLS (NCI) C0341335) =Disease or Syndrome
|
- 15. CM
- [A form of mastocytosis characterized by mast cell infiltration of the skin. (WHO, 2001) — 2003 ( NCI )] (UMLS (NCI) C1136033) Cutaneous Mastocytosis =Disease or Syndrome ;
| - 37. CMV Esophagitis
- (UMLS (NCI) C0877119) Cytomegalovirus Esophagitis;
=Disease or Syndrome ;
|
- 16. CM 101
- (UMLS (NCI) C0284216) =Carbohydrate; Pharmacologic Substance ;
| - 38. CMV Gastritis
- (UMLS (NCI) C0877117) CMV-Related Gastritis;
Cytomegaloviral Gastritis;
Cytomegalovirus Gastritis;
Cytomegalovirus-Related Gastritis =Disease or Syndrome ;
|
- 17. cm2
- [LITERAL ( NCI )] (UMLS (NCI) C0439479) =Quantitative Concept
| - 39. CMV Gastroenteritis
- (UMLS (NCI) C0948037) Cytomegalovirus Gastroenteritis;
=Disease or Syndrome |
- 18. CMA-676
- (UMLS (NCI) C0677800) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 40. CMV Negative
- (UMLS (HL7) C1548973) =Idea or Concept =Blood Product Processing Requirements;
|
- 19. CMF
- (UMLS (NCI) C0950521) CTX/5-FU/MTX;
Cyclophosphamide/Fluorouracil/Methotrexate;
=Therapeutic or Preventive Procedure ;
| - 41. CMV pp65 Peptide
- [A peptide derived from cytomegalovirus (CMV) internal matrix protein pp65. CMV pp65 peptide antigen is used in recombinant vaccinia virus as an HLA-A-restricted epitope to produce vaccines against CMV infection, a serious complication of allogeneic bone marrow transplantation (BMT). In BMT, CMV infection may be prevented by passive immunization with donor-derived CMV-pp65-specific T-cell clones if provided early post-BMT. (NCI04) ( NCI )] (UMLS (NCI) C1327895) =Amino Acid, Peptide, or Protein; Pharmacologic Substance
|
- 20. CMF Regimen
- [A regimen consisting of cyclophosphamide, methotrexate, fluorouracil used in the adjuvant setting and also for the treatment of recurrent and metastatic breast cancer. ( NCI )] (UMLS (NCI) C0055982) =Therapeutic or Preventive Procedure
| - 42. CMV retinitis
- [opportunistic retinal herpes viral infection in AIDS. ( CSP )] (UMLS (CSP) C0206178) =Disease or Syndrome =CYTOMEGALOVIRAL DISEASE;
Eye Infections, Viral;
Keratitis, Herpetic;
opportunistic infection;
retinitis;
|
- 21. CMF(P)TH
- (UMLS (NCI) C0279322) =Therapeutic or Preventive Procedure
| - 43. CMV Safe
- (UMLS (HL7) C1548974) =Idea or Concept =Blood Product Processing Requirements;
|
- 22. CMFH
- (UMLS (NCI) C0280279) =Therapeutic or Preventive Procedure
| - 44. CMVIG
- [cytomegalovirus immune globulin, intravenous ( HL7V3.0 )] (UMLS (HL7) C0057002) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor =[IM500] IMMUNOGLOBULINS;
CMVIG;
Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType =CMVIG;
CYTOMEGALOVIRUS IMMUNE GLOBULIN 2.5 GM;
|
home
